<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228640</url>
  </required_header>
  <id_info>
    <org_study_id>EFFE-CT-01</org_study_id>
    <nct_id>NCT04228640</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Uthever NMN(Nicotinamide Mononucleotide, a Form of Vitamin B3)</brief_title>
  <acronym>NMN</acronym>
  <official_title>A Multicentre, Randomized, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN), an Orally Administered Supplementation in Middle Aged and Older Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EffePharm LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ProRelix Services LLP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EffePharm LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multi-center, two arm study in 66 healthy adults. Subjects will complete a&#xD;
      screening visit (V1, Day -7) to determine eligibility for the study based on Inclusion &amp;&#xD;
      Exclusion Criteria, patient history and safety measures. Eligibility confirmation will be&#xD;
      done on visit 2 (Day 1). Patients successfully completing screen will be assigned to either&#xD;
      of the two treatments. Subjects will receive the treatment for at-home use and will also be&#xD;
      given diaries for recording information of medication, and adverse events. At 2 different&#xD;
      intervals i.e. Day 30 and Day 60 (V3, V4) subjects will return to the clinic to review and&#xD;
      collect patient diaries, safety data and medication reconciliation. Efficacy and safety&#xD;
      assessments will be done at baseline, Day 30 and Day 60 .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty-six healthy male or female middle-aged or older subjects will be assigned in 1:1 ratio&#xD;
      to treatment with the test product, NMN or Placebo in this double-blind, randomized,&#xD;
      placebo-controlled study. All 66 enrolled subjects will be instructed to take two capsules of&#xD;
      either NMN or Placebo once a day after breakfast for 60 days daily. Subjects will be required&#xD;
      to use diaries to document the date and time of study treatments including any missed doses&#xD;
      and the occurrence of any adverse events.&#xD;
&#xD;
      The duration of each subject's participation in the study will be of 60 days.&#xD;
&#xD;
      Scheduled study visits will include:&#xD;
&#xD;
        -  Visit 1 (Screening, Day -4)&#xD;
&#xD;
        -  Visit 2 (Baseline/Randomization visit, Day 1)&#xD;
&#xD;
        -  Visit 3 (Day 30).&#xD;
&#xD;
        -  Visit 4 (End of study, Day 60) A window (Â± 2 days) will be considered acceptable for&#xD;
           each scheduled visit following the baseline visit.&#xD;
&#xD;
      During Visit 1 (Screening), informed consent will be obtained before any study procedures&#xD;
      take place. After subject has been consented, medical history will then be documented,&#xD;
      including the concomitant medications (if any). Physical examination and ECG will be carried&#xD;
      out for all subjects. Subjects' vital signs will be recorded along with pulse pressure&#xD;
      (PP).Their laboratory investigations like Hematology, Clinical chemistry and Urinalysis will&#xD;
      be done. They shall undergo the screening procedure by inclusion and exclusion criteria.&#xD;
      Subject's demography data will be collected. They will be given instructions for the next&#xD;
      visit.&#xD;
&#xD;
      At Visit 2 (Day 1, Baseline visit), eligibility confirmation will be done, and each enrolled&#xD;
      subject will be randomly assigned in double-blind fashion, in 1:1 ratio to the test product&#xD;
      or the Placebo. Blinded investigational product will be dispensed to subjects who meet all&#xD;
      the inclusion and none of the exclusion criteria. Subjects will be instructed to take two&#xD;
      capsules of the either placebo or NMN once a day with ambient temperature water after&#xD;
      breakfast. They shall be recording the dosing details in subject diaries. The first dose of&#xD;
      Investigational Product will be taken by the subject at home. Subjects will be evaluated&#xD;
      through SF-36 questionnaire for their health. They will be required to answer few questions&#xD;
      pertaining to their health. (PI, CRC or site staff will fill SF-36 questionnaire in visit 2,&#xD;
      3 and 4 by asking the subject). All the baseline assessments for efficacy will be performed.&#xD;
&#xD;
      At visit 3 (Day 30) and visit 4 (Day 60), subjects will return to the clinic to review and&#xD;
      collect subjects' diaries, safety data, and medication reconciliation. Efficacy and safety&#xD;
      assessments will be done at both the visits.&#xD;
&#xD;
      Subjects will be asked to bring their subject diaries and used/unused Investigational&#xD;
      Products every time they visit the site. Enough quantity of Investigational Product will be&#xD;
      dispensed every visit. Subjects' vital signs will be recorded along with pulse pressure (PP)&#xD;
      at all visits. Adverse event assessment and concomitant assessment will be done at each visit&#xD;
      along with compliance with drug applications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">February 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Multicenter, Randomized, Double-Blind, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomized, Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood cellular NAD+ concentration in serum</measure>
    <time_frame>Day 2</time_frame>
    <description>Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood cellular NAD+ concentration in serum</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood cellular NAD+ concentration in serum</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood cellular NADH concentration in serum</measure>
    <time_frame>Day 2</time_frame>
    <description>Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood cellular NADH concentration in serum</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood cellular NADH concentration in serum</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Six minutes walking endurance test</measure>
    <time_frame>Day 2</time_frame>
    <description>Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Six minutes walking endurance test</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Six minutes walking endurance test</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic</measure>
    <time_frame>Day 2</time_frame>
    <description>Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>Day 2</time_frame>
    <description>Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse pressure</measure>
    <time_frame>Day 2</time_frame>
    <description>Evaluation of Pulse Pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse pressure</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Pulse Pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse pressure</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Pulse Pressure inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 questionnaire</measure>
    <time_frame>Day 2</time_frame>
    <description>Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 questionnaire</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 2</time_frame>
    <description>Evaluation of Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (blood chemistry)</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (blood chemistry)</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (blood chemistry)</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (lipid profile)</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of Laboratory parameter (lipid profile) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (lipid profile)</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Laboratory parameter (blood chemistry, lipid profile, LFT and RFT) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (lipid profile)</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Laboratory parameter (lipid profile) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (LFT )</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (LFT)</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (LFT)</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (RFT)</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (RFT)</measure>
    <time_frame>Day 30</time_frame>
    <description>Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameter (RFT)</measure>
    <time_frame>Day 60</time_frame>
    <description>Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop out due to adverse events</measure>
    <time_frame>Day 2</time_frame>
    <description>Number of participants that dropout due to adverse events including lab values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop out due to adverse events</measure>
    <time_frame>Day 30</time_frame>
    <description>Number of participants that dropout due to adverse events including lab values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop out due to adverse events</measure>
    <time_frame>Day 60</time_frame>
    <description>Number of participants that dropout due to adverse events including lab values</description>
  </secondary_outcome>
  <other_outcome>
    <measure>BMI</measure>
    <time_frame>Day 1</time_frame>
    <description>Monitoring of BMI inter group comparison from baseline to the end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>BMI</measure>
    <time_frame>Day 2</time_frame>
    <description>Monitoring of BMI inter group comparison from baseline to the end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>BMI</measure>
    <time_frame>Day 30</time_frame>
    <description>Monitoring of BMI inter group comparison from baseline to the end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>BMI</measure>
    <time_frame>Day 60</time_frame>
    <description>Monitoring of BMI inter group comparison from baseline to the end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>HOMA</measure>
    <time_frame>Day 2</time_frame>
    <description>Monitoring of HOMA inter group comparison from baseline to the end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>HOMA</measure>
    <time_frame>Day 60</time_frame>
    <description>Monitoring of HOMA inter group comparison from baseline to the end of study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Investigational Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ingredient: NMN Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ingredient: Starch powder Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NMN</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Investigational Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starch Powder</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/females of 40 to 65 years of age&#xD;
&#xD;
          2. Body Mass Index (BMI) between 18.5 and 35 kg/m2&#xD;
&#xD;
          3. Able to provide written Informed Consent&#xD;
&#xD;
          4. Able to follow verbal and written study directions&#xD;
&#xD;
          5. Must not be taking or be willing to take any supplements containing any form of niacin&#xD;
             for seven days prior to baseline and for the duration of the study.&#xD;
&#xD;
          6. Able to maintain consistent diet and lifestyle habits throughout the study&#xD;
&#xD;
          7. Male and female subjects must be willing to agree to use effective contraceptive&#xD;
             methods while on treatment and for 3 months after the completion of study&#xD;
&#xD;
          8. Willing to consume assigned dietary supplements for 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants on current use of prescription or over-the-counter nicotinic acid&#xD;
&#xD;
          2. Use of statin drugs&#xD;
&#xD;
          3. Having used any tobacco product or used a recreational drug in the past 6 months&#xD;
&#xD;
          4. Having abnormal screening laboratory test values or other lab test result(s) that&#xD;
             would preclude study participation in the judgment of the investigator&#xD;
&#xD;
          5. Documented presence of atherosclerotic disease and/or cardiopulmonary disease&#xD;
&#xD;
          6. History of drug or alcohol abuse&#xD;
&#xD;
          7. History of unstable depression or mental illness within the last 6 months for which&#xD;
             the investigator believes could impact the participant's ability to comply with study&#xD;
             requirements&#xD;
&#xD;
          8. Unwilling to discontinue use of conventional multivitamin/mineral or other supplements&#xD;
             at least two weeks prior to the study start&#xD;
&#xD;
          9. Participating in or planning to begin a weight loss diet during the study period&#xD;
&#xD;
         10. Chronic use of over-the-counter medication which would interfere with study endpoints&#xD;
&#xD;
         11. Lifestyle or schedule incompatible with the study protocol&#xD;
&#xD;
         12. Known hypersensitivity to the drug components used during the study&#xD;
&#xD;
         13. Women with positive result for urinary beta human chorionic gonadotropin or gestation&#xD;
             period or breastfeeding&#xD;
&#xD;
         14. Other diseases or medications, according to the investigator, that would interfere&#xD;
             directly in the results of the study or jeopardize the health of the participant.&#xD;
&#xD;
         15. Currently, or within the past 30 days, enrolled in a different clinical investigation&#xD;
&#xD;
         16. Inability to provide a venous blood sample&#xD;
&#xD;
         17. Unable or unwilling to provide written informed consent for participation in study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ganesh Avhad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swasthiye Clinic and Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Kamalakar Gajarae</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swasthiye Clinic and Research Center</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti- Aging</keyword>
  <keyword>Workout Enhancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

